A practical reference on Thymosin fraction 5: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
However, a 2015 estimate that used a new method for calibrating molecular clocks confirmed that while modern birds originated early in the Late Cretaceous, likely in Western Gondwana, a pulse of diversification in all major groups occurred around the Cretaceous–Palaeogene extinction event. Modern birds would have expanded from West Gondwana through two routes. One route was an Antarctic interchange in the Paleogene. The other route was probably via Paleocene land bridges between South America and North America, which allowed for the rapid expansion and diversification of Neornithes into the Holarctic and Paleotropics. On the other hand, the occurrence of Asteriornis in the Northern Hemisphere suggest that Neornithes dispersed out of East Gondwana before the Paleocene.
Oplophorus-luciferin 2-monooxygenase (EC 1.13.12.13), also known as Oplophorus luciferase (referred in this article as OpLuc) is a luciferase, an enzyme, from the deep-sea shrimp Oplophorus gracilirostris, belonging to a group of coelenterazine luciferases. Unlike other luciferases, it has a broader substrate specificity and can also bind to bisdeoxycoelenterazine efficiently. It was the third example of a luciferase (Other than Aequorea and Renilla) to be purified in lab. The systematic name of this enzyme class is Oplophorus-luciferin:oxygen 2-oxidoreductase (decarboxylating). This enzyme is also called Oplophorus luciferase.
phase diagram A graphical representation of the equilibrium relationships between thermodynamically distinct phases of a chemical compound, mixture, or solution, indicating the physical conditions (e.g. temperature and pressure) under which various phases (e.g. solid, liquid, and vapor) occur or coexist.
=== Death fold === Proteins with a death domain (DD), such as PIDD1, are defined by a structural framework consisting of six α-helical bundles, referred to as a 'death fold'. This structure is also present in other proteins that contain domains like the caspase recruitment domain (CARD), death effector domain (DED), pyrin domain (PYD), or combinations of these motifs (e.g., DD/CARD, DD/DED, PYRIN/CARD). These death folds facilitate homotypic protein-protein interactions (such as DD/DD or CARD/CARD), enabling the formation of large multi-protein signaling complexes. Notable examples include the apoptosome, which contains apoptotic protease-activating factor 1 (APAF1) and caspase-9, and the death-inducing signaling complex (DISC) associated with caspase-8 and members of the tumor necrosis factor receptor (TNFR) superfamily.
Sources: en.wikipedia.org
The bacteria might induce systemic resistance in the host plant, so it can better resist attack by a true pathogen. The bacteria might outcompete other (pathogenic) soil microbes, e.g., by siderophores, giving a competitive advantage at scavenging for iron. The bacteria might produce compounds antagonistic to other soil microbes, such as phenazine-type antibiotics or hydrogen cyanide. To be specific, certain P. fluorescens isolates produce the secondary metabolite 2,4-diacetylphloroglucinol (2,4-DAPG), the compound found to be responsible for antiphytopathogenic and biocontrol properties in these strains. The phl gene cluster encodes factors for 2,4-DAPG biosynthesis, regulation, export, and degradation. Eight genes, phlHGFACBDE, are annotated in this cluster and conserved organizationally in 2,4-DAPG-producing strains of P. fluorescens. Of these genes, phlD encodes a type III polyketide synthase, representing the key biosynthetic factor for 2,4-DAPG production. PhlD shows similarity to plant chalcone synthases and has been theorized to originate from horizontal gene transfer. Phylogenetic and genomic analysis, though, has revealed that the entire phl gene cluster is ancestral to P. fluorescens, many strains have lost the capacity, and it exists on different genomic regions among strains. Some experimental evidence supports all of these theories, in certain conditions; a good review of the topic is written by Haas and Defago. Several strains of P. fluorescens, such as Pf-5 and JL3985, have developed a natural resistance to ampicillin and streptomycin.
Argon (18Ar) has 26 known isotopes, from 29Ar to 54Ar, of which three are stable (36Ar, 38Ar, and 40Ar). On Earth, 40Ar makes up 99.6% of natural argon. The longest-lived radioactive isotopes are 39Ar with a half-life of 302 years, 42Ar with a half-life of 32.9 years, and 37Ar with a half-life of 35.01 days. All other isotopes have half-lives of less than two hours, and most less than one minute. Isotopes lighter than 38Ar decay to chlorine or lighter elements, while heavier ones beta decay to potassium. The naturally occurring 40K, with a half-life of 1.248×109 years, decays to stable 40Ar by electron capture (10.72%) and by positron emission (0.001%), and also to stable 40Ca via beta decay (89.28%). These properties and ratios are used to determine the age of rocks through potassium–argon dating. Despite the trapping of 40Ar in many rocks, it can be released by melting, grinding, and diffusion. Almost all argon in the Earth's atmosphere is the product of 40K decay, since 99.6% of Earth's atmospheric argon is 40Ar, whereas in the Sun and presumably in primordial star-forming clouds, argon consists of ~85% 36Ar, ~15% 38Ar and only trace 40Ar. Similarly, the ratio of the isotopes 36Ar:38Ar:40Ar in the atmospheres of the outer planets is measured to be 8400:1600:1. In the Earth's atmosphere, radioactive 39Ar (and to a lesser extent 37Ar) is made by cosmic ray activity, primarily from 40Ar.
In 2006 he finished the book Beyond the Setting Sun, with an introduction by Ranulph Fiennes, the renowned polar explorer and adventurer. The book was written to raise money for hospices in Britain, Canada and America.
=== 2013–2020: R40 Tour, disbandment and Peart's death === On November 18, 2013, Lifeson said that the band would take a year off after the completion of the world tour in support of Clockwork Angels. "We've committed to taking about a year off", Lifeson said. "We all agreed when we finished this [Clockwork Angels] tour [in early August], we were going to take this time off and we weren't going to talk about band stuff or make any plans. We committed to a year, so that's going to take us through to the end of next summer, for sure. That's the minimum. We haven't stopped or quit. Right now we're just relaxing. We're taking it easy and just enjoying our current employment." In September 2014, the Rush R40 box set was announced to commemorate the 40th anniversary of the release of the band's self-titled debut album. It included five previously released live video albums, and various previously unreleased footage from across the band's career. On January 22, 2015, the band announced the Rush R40 Tour, celebrating the 40th anniversary of Peart's membership in the band. The tour started on May 8 in Tulsa, Oklahoma, and wrapped up on August 1 in Los Angeles. On April 29, 2015, Lifeson said in an interview that R40 might be the final large-scale Rush tour due to his psoriatic arthritis and Peart's chronic tendinitis. He noted that it did not necessarily mean an end to the band, suggesting the possibility of smaller tours and limited performances. He said that he wanted to work on soundtracks with Lee. On December 7, 2015, Peart stated in an interview that he was retiring.
In April 1943, paratroopers from the 82nd, under the command of Major General Ridgway, sailed into the Mediterranean Theater of Operations and landed in North Africa as part of the Allied plan to invade Sicily. The division's first two combat operations were parachute assaults into Sicily on 9 July and Salerno on 13 September 1943. The initial assault on Sicily, by the 505th Parachute Regimental Combat Team, under Colonel Gavin, was the first regimental-sized combat parachute assault conducted by the United States Army. The first glider assault did not occur until Operation Neptune as part of the D-Day landings of 6 June 1944. Troopers arrived in Italy by landing craft at Maiori, Naples, and Salerno. During the invasion of Italy, Ridgway considered Will Lang Jr. of TIME magazine an honorary member of the division. In January 1944, the 504th, commanded by Colonel Reuben Tucker, which was temporarily detached to fight at Anzio, adopted the nickname "Devils in Baggy Pants", taken from an entry in a German officer's diary.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.